These evidences promote us to feel great interest in determining the significance of DAB2IP, as an identified repressive target gene of EZH2, in CRT sensitivity and its effect on the prognosis of ESCC patients treated with definite CRT. This evidence concerns the gene EZH2 and esophageal squamous cell carcinoma.